Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. Revance Therapeutics, Inc. has a collaboration agreement with Mylan N.V. (MYL) for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RVNC
CUSIPN/A
Phone510-742-3400
Debt
Debt-to-Equity RatioN/A
Current Ratio8.58
Quick Ratio8.58
Price-To-Earnings
Trailing P/E Ratio-6.53
Forward P/E Ratio-6.72
P/E GrowthN/A
Sales & Book Value
Annual Sales$260,000.00
Price / Sales3,722.42
Cash FlowN/A
Price / CashN/A
Book Value$7.51 per share
Price / Book3.49
Profitability
EPS (Most Recent Fiscal Year)($4.01)
Net Income$-120,580,000.00
Net Margins-13,690.62%
Return on Equity-63.30%
Return on Assets-53.80%
Miscellaneous
Employees134
Outstanding Shares36,940,000
Market Cap$978.85 million
Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions
What is Revance Therapeutics' stock symbol?
Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."
How were Revance Therapeutics' earnings last quarter?
Revance Therapeutics Inc (NASDAQ:RVNC) announced its earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.92) by $0.02. The biopharmaceutical company had revenue of $0.69 million for the quarter, compared to the consensus estimate of $0.93 million. Revance Therapeutics had a negative net margin of 13,690.62% and a negative return on equity of 63.30%. View Revance Therapeutics' Earnings History.
When is Revance Therapeutics' next earnings date?
What price target have analysts set for RVNC?
11 brokerages have issued 1 year price objectives for Revance Therapeutics' shares. Their predictions range from $34.00 to $60.00. On average, they anticipate Revance Therapeutics' share price to reach $47.20 in the next twelve months. This suggests a possible upside of 80.2% from the stock's current price. View Analyst Price Targets for Revance Therapeutics.
What is the consensus analysts' recommendation for Revance Therapeutics?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Revance Therapeutics.
What are Wall Street analysts saying about Revance Therapeutics stock?
Here are some recent quotes from research analysts about Revance Therapeutics stock:
- 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (8/9/2018)
- 2. Cantor Fitzgerald analysts commented, "We expect upward earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. These could come from positive news flow for Revance’s key programs in development. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12- month price target of $50 and Overweight rating." (5/29/2018)
Who are some of Revance Therapeutics' key competitors?
Some companies that are related to Revance Therapeutics include Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Array Biopharma (ARRY), Opko Health (OPK), Blueprint Medicines (BPMC), Heron Therapeutics (HRTX), Akcea Therapeutics (AKCA), Amicus Therapeutics (FOLD), Ironwood Pharmaceuticals (IRWD) and The Medicines (MDCO).
Who are Revance Therapeutics' key executives?
Revance Therapeutics' management team includes the folowing people:
- Mr. L. Daniel Browne, Co-Founder, CEO, Pres & Director (Age 56)
- Dr. Abhay Joshi, Chief Operating Officer (Age 55)
- Mr. Todd Erik Zavodnick, Chief Commercial Officer and Pres of Aesthetics & Therapeutics (Age 46)
- Mr. Cyril Allouche, Head of Fin., Interim Principal Fin. & Accounting Officer and Corp. Controller (Age 46)
- Ms. Caryn Gordon McDowell, Sr. VP, Gen. Counsel & Corp. Sec. (Age 48)
Has Revance Therapeutics been receiving favorable news coverage?
Headlines about RVNC stock have trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Revance Therapeutics earned a coverage optimism score of 0.11 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.87 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Revance Therapeutics.
Who are Revance Therapeutics' major shareholders?
Revance Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.94%), Bank of New York Mellon Corp (5.29%), Jennison Associates LLC (3.08%), Millennium Management LLC (2.93%), Fosun International Ltd (1.28%) and OppenheimerFunds Inc. (0.68%). Company insiders that own Revance Therapeutics stock include Cyril Allouche, L Daniel Browne, Lauren P Silvernail, Mark J Foley and Phyllis Gardner. View Institutional Ownership Trends for Revance Therapeutics.
Which institutional investors are selling Revance Therapeutics stock?
RVNC stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Jennison Associates LLC, FMR LLC, Bank of New York Mellon Corp, Essex Investment Management Co. LLC, Fred Alger Management Inc., Alps Advisors Inc. and Alps Advisors Inc.. Company insiders that have sold Revance Therapeutics company stock in the last year include Cyril Allouche, L Daniel Browne, Lauren P Silvernail and Phyllis Gardner. View Insider Buying and Selling for Revance Therapeutics.
Which institutional investors are buying Revance Therapeutics stock?
RVNC stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Fosun International Ltd, Sio Capital Management LLC, Bank of America Corp DE, Renaissance Technologies LLC, Los Angeles Capital Management & Equity Research Inc., First Midwest Bank Trust Division and OppenheimerFunds Inc.. View Insider Buying and Selling for Revance Therapeutics.
How do I buy shares of Revance Therapeutics?
Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Revance Therapeutics' stock price today?
One share of RVNC stock can currently be purchased for approximately $26.20.
How big of a company is Revance Therapeutics?
Revance Therapeutics has a market capitalization of $978.85 million and generates $260,000.00 in revenue each year. The biopharmaceutical company earns $-120,580,000.00 in net income (profit) each year or ($4.01) on an earnings per share basis. Revance Therapeutics employs 134 workers across the globe.
How can I contact Revance Therapeutics?
Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected]
MarketBeat Community Rating for Revance Therapeutics (NASDAQ RVNC)
MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe RVNC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVNC will underperform the S&P 500 over the long term. You may vote once every thirty days.
